Manchester Science Partnerships (MSP) is to invest £60 million in a major expansion of Citylabs, its biomedical centre of excellence, in partnership with Central Manchester University Hospitals NHS Foundation Trust (CMFT). In a major vote of confidence for the Manchester city region, the development will create Citylabs 2.0 and Citylabs 3.0 on the CMFT campus, in the heart of Manchester’s Innovation District, Corridor Manchester.
The new development will provide additional space to enable biomedical companies to grow and co-create new health products, in collaboration with the NHS and academia for the benefit of patients. It is anticipated that when both are completed and fully let, Citylabs 2.0 and 3.0 will bring additional economic growth in excess of £100 million and over 750 new jobs to the city.
The project is the first to be delivered by the Strategic Property Partnership between MSP's parent company, Bruntwood, and CMFT. Announced in March, the partnership will support the delivery of clinical care, research and innovation, as well as the future development of CMFT’s estate.
Steve Mycio, CMFT Chairman, said: “By working together in this way with industry, the NHS can ensure health technologies are developed that deliver better outcomes more efficiently to meet current and future needs of our patients and healthcare providers.
“Citylabs 2.0 and 3.0 is our first scheme under the Strategic Property Partnership that CMFT has formed with Bruntwood. Its purpose is to help ensure that our hospital building and facilities are developed in a flexible and modern way to facilitate early access to new diagnostics and treatments.”